In the relatively short time frame since the introduction of next generation sequencing, it has become a method of choice for complex genomic research studies. As a paradigm shifting technology, we are now witnessing its translation into clinical diagnostic laboratories for patient care. Multi-gene panels for a variety of disorders are now available in several clinical laboratories based on targeted gene enrichment followed by next generation sequencing. Genome wide interrogation of protein coding regions, or exome sequencing, has been successfully and increasingly applied in the research setting for the elucidation of candidate genes and causal variants in individuals and families with a diversity of rare and complex genetic disorders. Based on this progress, exome sequencing is also beginning a translational process into clinical practice. However, introducing exome sequencing as a diagnostic modality poses new technical and bioinformatics challenges for clinical laboratories. In this review, we present technical and bioinformatics aspects of exome sequencing, describe representative examples from the literature of how exome sequencing has been used for candidate gene discovery, and discuss considerations for its clinical translation.
Introduction
Next generation sequencing (NGS) is beginning to be implemented in clinical diagnostic laboratories. Its high throughput capacity allows a new approach for analysis and diagnosis of genetic disorders that have been otherwise diffi cult or cost prohibitive to investigate. These include diseases which result from deleterious variants in multiple genes whose proteins are involved in signaling pathways and structure function complexes. Examples include inherited cardiomyopathies, mitochondrial disorders, and metabolic disorders, among others (1 -6) . In this context, NGS is being used to sequence disorder-specifi c gene panels ranging from several to over 100 genes. While offering a more comprehensive approach than classical diagnostic strategies, there will be inconclusive cases if the patient ' s causative variants reside in another gene or non-coding region that was not included in the panel. In these cases, genome wide sequencing and analytical strategies will be necessary to elucidate causal variants. As costs decrease, whole genome sequencing (WGS) may become the preferred genome wide diagnostic approach. However, the complexity of bioinformatics resources currently necessary for WGS analysis remain out of reach for the majority of clinical laboratories. Further, while we have considerable knowledge of the role of specifi c genes in disease pathogenesis, our understanding of the contribution of variants in intergenic regions is limited. As an alternative, sequencing all known coding regions, or exome sequencing, has gained considerable traction as a candidate gene discovery tool due to its lower cost and more manageable dataset (7) . In this review, technical and bioinformatics aspects of exome sequencing are presented, how exome sequencing has been employed to identify candidate genes in several inheritance scenarios is summarized, and considerations for clinical translation are discussed.
Technical and bioinformatics considerations for exome sequencing
The exome is operationally defi ned by the consensus coding sequence (CCDS) database, a consortium effort to delineate human coding sequences. There are currently 25,564 unique CCDS ID numbers corresponding to 18,407 human genes ( http://www.ncbi.nlm.nih.gov/CCDS/CcdsBrowse.cgi ). Exons and splice site boundaries harbor approximately 85 % of identifi ed causal variants of Mendelian diseases to date, a fi nding that supports using exome sequencing in causative variant discovery (8) . An advantage of exome sequencing over traditional linkage analysis is that sequence information from one or a few individuals can lead to causative variant discovery (9) . Exome sequencing does not require a priori knowledge of the gene(s) responsible for a disorder and is therefore a " hypothesis free " method of discovery compared to gene panel approaches. However, a typical exome sequencing study yields approximately 15,000 -20,000 coding variants that differ from the human reference sequence and the outstanding bioinformatics challenge is identifying causal variants among a majority of benign polymorphisms.
Multiple laboratory steps are involved in exome sequencing and include: 1) genomic DNA fragmentation; 2) conversion of fragments into a NGS library; 3) capture probe hybridization based enrichment of exome sequences from the library; and 4) next generation sequencing. Genomic DNA fragmentation by currently utilized techniques, such as nebulization, sonication, or restriction digestion, results in DNA fragments in the 200 -600 base pair size range depending on fragmentation method and exome protocol requirements. After fragmentation, the DNA must be enzymatically end repaired prior to ligation of platform specifi c adapter oligonucleotides, which can be performed manually or on automated platforms. A PCR step with primers complementary to adapter sequences increases library concentration prior to exome capture. Several commercial vendors offer in-solution exome capture reagents including Agilent (Santa Clara, CA, USA), Roche NimbleGen (Madison, WI, USA), and Illumina (San Diego, CA, USA), each differing in probe sequence composition and performance characteristics as summarized in Table 1 . For exome enrichment, PCR amplifi ed library preparations are hybridized with a pool of exon specifi c capture probes. Hybridized probe and library complexes are captured on beads, unbound DNA is washed away, and bead-bound library is used as template for PCR amplifi cation, yielding an exome enriched library. Libraries are assessed for quality and fragment size by electrophoresis and subjected to quantitative PCR (qPCR) with adapter specifi c primers for determination of concentration. Commercially available sequencing platforms with the throughput capacity for exome sequencing include the Roche 454 GS-FLX (Branford, CT, USA), the Illumina Genome Analyzer and HiSeq (San Diego, CA, USA), and Life Technologies ' SOLiD instruments (Carlsbad, CA, USA). The fundamentals of each instrument ' s sequencing chemistry have been described in other recent reviews (1, 10) . To leverage instrument throughput and reduce costs, molecular indexes (i.e ., barcodes) can be incorporated into the adapter sequences of individual exome libraries allowing pooling and simultaneous sequencing of several indexed libraries. Indexing strategies should take into account reduced per sample read coverage, the required minimum read coverage for targeted exons with known low read coverage, and variant calling accuracy.
At our institution, we currently perform NimbleGen based exome capture followed by paired-end 100 base length read sequencing chemistry on the Illumina HiSeq2000 platform to generate ∼ 150 million reads per exome in a single fl ow cell lane. Here we present several bioinformatics tools and approaches for data analysis used in our laboratory. Sequencing reads are fi rst aligned to the GRCh37 reference sequence with subsequent variant calling ( Figure 1 ). Multiple programs are used to handle this task including the open source software Burrows-Wheeler Aligner (BWA ( http://bio-bwa.sourceforge. net ) (11) , Novoalign ( http://www.novocraft.com/mail/index. php ), Genome Analysis Toolkit (GATK, http:://www.broadinstitute.org/gsa/wiki/index.php/The_Genome_Analysis_ Toolkit) (12, 13) and SAMTools ( http://samtools.sourceforge. net ) (14) . Novoalign and BWA align the paired-end 100 base reads to the reference sequence and both SAMTools and GATK call single nucleotide variants (SNVs), as well as short insertion, deletion, and indel variants. GATK executes local realignments around insertions or deletions and base quality score recalibration. ANNOVAR ( http://www.openbioinformatics.org/annovar/ ) (15) and GATK may both be employed for variant annotation. Optional removal of PCR duplicates prior to variant calling is performed with PICARD ( http:// picard.sourceforge.net/ ). The above programs are designed to run on Linux or UNIX platforms and require considerable computing power for timely data processing. A variant list generated with these tools contains annotated information, such as base change from reference, location of the change (e.g., exon, intron, splice site), the consequence of the change to the codon (e.g., synonymous vs. non-synonymous, missense vs. frameshift), and zygosity (e.g., homozygous or heterozygous). This data set also contains read coverage depth, mapping, and base quality scores.
Candidate gene and pathogenic variant identifi cation
With an annotated gene list, several strategies can be implemented in an effort to identify candidate genes and causal variants ( Figure 1) . A common fi rst step in family studies is to apply fi lters based on suspected disease inheritance patterns and disease frequency. In a presumed rare inherited disorder, the fi rst step is removal of all variants catalogued in public resources, such as dbSNP, the 1000 Genomes project, or from in-house databases. This initial fi lter typically reduces the variant list by about 95 % from approximately 20,000 -1000 high quality variants. An important caveat, however, is that dbSNP does contain a few known rare pathogenic variants as well as more common variants indicated by genome-wide association studies. An alternative approach is to remove dbSNP and 1000 genomes variants with population variant frequencies above a certain threshold assuming that common variants are non-pathogenic. Additionally, genes with known associations with the patient ' s disorder can be specifi cally investigated for causative variants. If linkage or shared genomic segment data is available in the setting of a kindred study, then the search for causative variants can be focused to those regions (16) . Variants with the most likely deleterious changes, such as nonsense, missense, and frameshifts are prioritized. Indels and missense variants should be Bioinformatic workfl ow for alignment, annotation, and identifi cation of candidate genes and potential causative variants generated from next generation sequencing. Examples of software options for process steps and databases used for fi ltering are indicated.
considered along with zygosity, disease inheritance pattern, and predicted functional effect of the variant on the protein, the latter assessed with programs, such as Sorting Intolerant from Tolerant (SIFT), Genomic Evolutionary Rate Profi ling (GERP), and Polymorphism Phenotyping (PolyPhen). Each candidate gene is then evaluated for its biological relevance to the disease being studied and whether it has been implicated in that disease by cross referencing databases, such as Human Gene Mutation Database (HGMD), Online Mendelian Inheritance in Man (OMIM), and locus specifi c databases. If multiple affected and/or unaffected individuals are sequenced, then intersect and difference fi lters can be applied to identify variants that co-segregate with affected individuals. In kindred studies, unaffected individuals in a family with a recessive inheritance pattern may be carriers so the zygosity of the variant must be considered before removing variants at identical chromosomal positions between individuals.
As a quality check, it is important to verify the candidate variants using the NGS read data. Inspection of the sequence reads is critical to identify potential false positive variants due, e.g., to misalignment. One viewer used frequently in the author ' s laboratory is the open-source Integrated Genomics Viewer (IGV, http://www.broadinstitute.org/igv). A representative viewer image is shown in Figure 2 along with Sanger sequencing traces. In this example, a mother has a heterozygous C > T change on the X chromosome while one son inherited the variant and the other son is wild type with respect to the reference.
While fi ltering and intersection approaches have been leveraged to identify candidate genes in a variety of disorders (see below), new prediction algorithms are being developed. One such algorithm is the Variant Annotation, Analysis, and Selection Tool (VAAST). VAAST is a probabilistic search tool that compares allele frequencies between cases and controls to identify candidate variants and models variant severity with tools, such as amino acid substitution analysis. This combined approach was recently used to successfully identify a disease causing variant in a previously uncharacterized, rare X-linked Mendelian disorder termed N-terminal acetyltransferase defi ciency (OMIM # 300013) (17, 18) .
Functional analysis
Once a candidate gene with predicted deleterious variants has been identifi ed and verifi ed, follow up genetic and/or functional studies are important to establish causality. In some cases, the candidate gene has already been associated with the patient phenotype, while the variant is novel. If no previous association has been reported, screening for either the same or other variants in the candidate gene in patients with similar signs and symptoms along with unaffected controls is warranted. Even with a strong candidate variant, the best evidence for causality comes from in vitro and in vivo functional studies in cells and animal models. In some cases, additional clinical laboratory testing in the patient can be informative and supportive of a role for the candidate gene in pathogenesis. 
Exome sequencing: progress to date

Monogenic diseases
In a landmark proof of principle study, Ng et al. (19) used exome sequencing on four affected but unrelated individuals affl icted with the rare autosomal dominant Freeman-Sheldon syndrome (OMIM # 193700) to identify variants within the MYH3 gene. Freeman-Sheldon syndrome is characterized by skeletal malformations and unique dysmorphic facial features. The authors fi rst identifi ed approximately 2500 genes common between the four affected individuals that contained non-synonymous or splice site variants and coding indels.
They then removed variants found in dbSNP and in eight HapMap exomes. Using this variant fi ltering approach, the only remaining gene which contained predicted deleterious variants common to all four individuals was MYH3 , a gene previously implicated in Freeman-Sheldon syndrome. Since this initial study, a growing number of reports have described the successful application of exome sequencing in identifying causative variants in disorders with recessive and dominant inheritance patterns as well as in disorders caused by de novo variants (9, 20 -22) . Several examples are discussed next.
Exome sequencing has been used to elucidate the genetic basis of a clinical diagnosis. For example, Choi et al. (23) sequenced the exome of an infant from consanguineous parents thought to have recessive Bartter syndrome (OMIM # 607364), a disorder caused by a renal defect in sodium reabsorption, and found a homozygous missense variant in SLC26A3 , a gene known to cause recessive congenital chloride diarrhea (OMIM # 214700). Five out of 39 patients previously diagnosed with Bartter syndrome also had deleterious variants in this gene, thus leading to a more precise genetic diagnosis of congenital chloride diarrhea, which was confi rmed by further clinical testing in three cases. In an example of how heterogeneous symptoms can be clarifi ed by exome sequencing, Ng et al. (24) identifi ed causative variants in the DHODH gene in two affected siblings from one kindred and two unrelated affected individuals affl icted with the recessive craniofacial limb malformation disorder termed Miller syndrome (OMIM # 263750). The two affected siblings also had a second variant in DNAH5 , a gene with variants implicated in autosomal recessive primary ciliary dyskinesia (OMIM # 608644). This DNAH5 variant explained pulmonary symptoms in these individuals, namely recurrent lung infections, bronchiectasis, and chronic obstructive pulmonary disease.
Causative variants are not always obvious because of the assumptions made during data analysis. In a study by Ng et al. (25) , 10 unrelated probands were exome sequenced in an effort to uncover the genetic basis of autosomal dominant Kabuki syndrome characterized by cardiac and skeletal abnormalities, immunological defects, characteristic facial structure, and mild to moderate intellectual disability (OMIM # 147920). Initially, the investigators applied standard fi lters and looked for genes containing novel, deleterious variants shared by all 10 cases but this approach did not uncover a solid candidate gene. The authors then stratifi ed the cases based on symptom severity, applied standard fi lters, and looked for novel deleterious variants present in the same gene in two or more cases. The most severe case had 25 genes with novel loss of function mutations; adding the second most severe case decreased the list to one gene, MLL2 , in which variants were identifi ed in nine of 10 cases. Sanger sequencing of MLL2 uncovered novel deleterious variants in 26 of 43 additional cases, supporting its role in Kabuki syndrome.
De novo SNV detection
Certain disorders, such as intellectual disability, persist in the population even though it is uncommon for severely affected individuals to have children. One proposed explanation for this phenomenon is that a proportion of cases are due to deleterious variants that arise de novo in the population. Evidence supporting this hypothesis has recently been generated using exome sequencing in studies of intellectual disability (22) , autism (21) , and schizophrenia (20) . All three groups sequenced parents and affected individuals (trios) in kindreds with no family history of the respective disorder. Vissers et al. (22) 
Complex diseases
Although exome sequencing has primarily been used in studies of monogenic disorders, it also offers a new approach for identifying causative variants in heterogeneous, complex diseases. Parkinson disease (OMIM # 168600) is the second most common neurodegenerative disorder affecting 1 % of people older than 65 years (26) . Of affected individuals, approximately 14 % have at least one relative with the disease (27) . Currently, no molecular diagnostic test is available for sporadic cases; instead, diagnoses are made based on clinical observations making the incidence of misdiagnosis high and pre-symptomatic or prenatal testing not possible (28) . Causative variants in only six genes had been identifi ed in familial cases prior to the recent identifi cation by exome sequencing of predicted causative variants in the gene VPS35 in two unrelated kindreds (29, 30) . VPS35 is a component of the retromer complex required for transport of cellular cargo through the endosomal network. Amyotrophic lateral sclerosis (ALS, OMIM # 105400), a progressive neurodegenerative disorder with a median life expectancy of 3 years post diagnosis, is another complex disease that would greatly benefi t from improved diagnostic testing. Only 5 % of ALS cases are familial, of which only ∼ 30 % are due to pathogenic variants in one of three known causative genes (31, 32) . Very recently, a defect in recycling and breakdown of proteins by the proteasomal system was proposed as an underlying molecular mechanism of disease progression (31) and, in a separate study, exome sequencing of an Italian kindred uncovered a causative variant in VCP , a gene involved in protein degradation (32) .
Translating exome sequencing into the diagnostic laboratory
The research achievements reported to date have led to increasing interest in applying exome sequencing to patient care, particularly in scenarios where other diagnostic testing has not been defi nitive. While conceptually attractive, implementation will be challenging for clinical laboratories. From a technical perspective, the current multi-step, multi-day protocols for in-solution exome capture require personnel to conduct high complexity manual protocols. Fortunately, a growing number of automation options are being introduced into the commercial market. Liquid handlers are now available that perform the majority of process steps for NGS library preparation and exome capture. While requiring additional capital investment, automating process steps for exome sequencing will increase throughput and improve consistency of results. As technical barriers are overcome, the greatest challenge to implementation will remain the time intensive process of bioinformatics analysis and data interpretation that is required to identify candidate genes and causal variants. Establishing a bioinformatics infrastructure, deciding which alignment, variant calling, and annotation algorithms to utilize, and determining how to validate the overall data analysis pipeline require expertise that is not resident in the majority of clinical laboratories. As an interim solution, clinical laboratories adopting exome sequencing often collaborate with research groups who have bioinformatics expertise to facilitate the launch of their programs and to cross train personnel in their laboratories. In the long-term, clinical laboratories will need to be staffed with bioinformatics specialists who analyze and collate data for medical interpretive review and who will keep pace with innovations in the continually evolving fi eld of genome data analysis.
Prior to clinical introduction, each laboratory should defi ne the performance characteristics of exome sequencing as conducted in their setting. This would include establishing their method ' s sensitivity, specifi city, accuracy and precision. As discussed above, vendor supplied exome capture reagents differ in their composition. For a given combination of reagents and sequencing platform it is critical to defi ne what percentage of the exome is effi ciently captured and accurately sequenced. Conversely, it is important to identify the regions of the exome that are diffi cult to capture or sequence, which is relevant to the false negative rate, and is particularly important in high priority candidate genes for the disorder under investigation. Figure 3 illustrates differences in exon capture between genes. The two genes shown were interrogated using the NimbleGen SeqCap in solution capture kit version 2.2, sequenced on an Illumina HiSeq, and viewed using the IGV. The right panel shows capture of a subset of exons in HLA-DOB . The HLA family of genes is diffi cult to capture using probe hybridization techniques because of high homology between family members. Of the six exons in HLA-DOB only two are captured. In contrast, all coding exons in the FOXP3 gene are captured using this approach. Seven representative FOXP3 exons are shown in the left panel of Figure 3 . Custom probes can be designed and added to the probe pool to increase candidate gene capture, if feasible and necessary. As a probe based method, exome capture not only enriches target sequences but also highly homologous pseudogenes and other homologous sequences, such as those present in gene families and domain analogs. The presence of co-captured sequences can confound interpretation when non-target, highly homologous sequences coalign to target gene reference sequences, resulting in false positive variant calls. . HLA-DOB belongs to a larger gene family with highly homologous sequences, making the design of unique capture probes diffi cult. As a result, only two exons shown here contain unique probes, are captured effi ciently, and can be aligned to the reference sequence, thus highlighting that problematic genomic regions are not included in capture probe design.
In translating exome sequencing into clinical practice, it is important to recognize its limitations and acknowledge that laboratory and clinical practice guidelines do not currently exist. With regard to technical limitations, commercially available exome capture reagents do not capture all exons in the genome as illustrated in Figure 3 and the genetic regions that are captured display variable depth of read coverage. This, in combination with the fact that only coding regions and a portion of fl anking intronic sequences are interrogated, reduces the method ' s diagnostic sensitivity. While published reports demonstrate the power of exome sequencing, anecdotal estimates for the method ' s ability to detect candidate genes and causal variants range from approximately 30 to at most 50 % (16) . A variety of factors likely infl uence the success rate of exome sequencing to detect causal variants and include the nature of the underlying genetic contributors, the criterion for case selection, such as age of onset and disease severity, the number of affected and unaffected individuals available for sequencing in a kindred study, and the data analysis algorithms employed. In this dynamic landscape, professional organizations have begun to address the challenges presented by the use of NGS for clinical diagnostics. Discussions focused on defi ning analysis metrics for read mapping and base quality scores, read coverage depth, sensitivity of variant detection, and requirements for variant confi rmation are ongoing. Essential elements, such as how to best conduct a validation study need to be determined. In parallel, recent studies in the literature reporting diagnoses based on exome and whole genome sequencing (33 -35) have stimulated debates about patient selection and what results, beyond those pertinent to the immediate clinical question, should be reported to patients (36, 37) .
Conclusions
This review has highlighted only a few of the very interesting and important studies that have been published in the past three years in which exome sequencing has added to our understanding of the genetic basis of disease. The emerging literature has demonstrated the ability of exome sequencing to uncover genetic contributors in rare Mendelian disorders with various inheritance patterns, complex diseases, and disorders arising from de novo mutational events. Continued improvements in exome capture reagents, sequencing chemistries and bioinformatics tools, coupled with further anticipated cost reductions, will expand the applications of exome sequencing and accelerate its translation into the clinical laboratory. The involvement of professional organizations, and their role in defi ning laboratory guidelines and best clinical practices, will be essential for optimizing the use of exome sequencing for patient care.
